Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 06/01/19991 min de lecture
Dipyridamole; Drugs for Human Use; Drug Efficacy Study Implementation; Withdrawal of Approval of Abbreviated New Drug Applications
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA) is withdrawing conditional approval of abbreviated new drug applications (ANDA's) and pertinent parts of ANDA's for certain dipyridamole drug products. FDA is also declaring three unapproved dipyridamole drug products unlawful. FDA is withdrawing approval because there is a lack of substantial evidence that these drugs are effective for long-term therapy of chronic angina pectoris.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →